http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CL-2017002284-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e398f26aef71c965698024f2771d68d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8203766bb5b0646a7d3ac0185bb2c7d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7d17974b4ffd9f0c248f0a213253ac4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0936f0277953ac18343ea98dc9e47b26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e9297ad3b4f195a396c717ee938d063 |
| publicationDate | 2018-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CL-2017002284-A1 |
| titleOfInvention | Use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines. |
| abstract | <p> The present invention relates to: - use of a 2,3-dihydroimidazo [1,2-c] quinazoline compound or a pharmaceutical composition containing it, as a single active agent or a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more other active agents, for the preparation of a medicament for the treatment or prevention of endometrial cancer (hereinafter, abbreviated as "EC") , in particular first-line, second-line, recurrent, refractory, type I or type II or endometriosis EC; - combinations of a) said compound and b) one or more other active agents; - a pharmaceutical composition comprising said compound as a single active agent for the treatment of endometrial cancer (hereinafter, abbreviated as "EC"), in particular first-line, second-line, recurrent, refractory EC , type I or type II or endometriosis; - a pharmaceutical composition comprising a combination of a) said compound and b) one or more other active agents; - use of biomarkers that is the loss of PTEN or FBXW7 tumor suppressor, to predict the sensitivity and / or resistance of a cancer patient to said compound and supply of a rational dose to increase sensitivity and / or to overcome resistance; - a method of determining the loss of PTEN or FBXW7 tumor suppressor; and a disturbance determination method in PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and / or FGFR4; PTEN loss and alteration of PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, FGFR1, FGFR2, FGFR3 and / or FGFR4. </p> |
| priorityDate | 2015-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 145.